Trial Profile

A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 30 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selinexor (Primary)
Indications Glioblastoma
Focus Therapeutic Use
Acronyms KING
Sponsors Karyopharm Therapeutics

Most Recent Events

02 Nov 2021 Results assessing intra-tumoral penetration, safety, and efficacy of selinexor monotherapy for recurrent glioblastoma published in the Clinical Cancer Research
30 Jul 2021 Status changed from completed to discontinued.
03 Nov 2020 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com